BR0314714A - Compostos para o tratamento da doença de alzheimer - Google Patents

Compostos para o tratamento da doença de alzheimer

Info

Publication number
BR0314714A
BR0314714A BR0314714-2A BR0314714A BR0314714A BR 0314714 A BR0314714 A BR 0314714A BR 0314714 A BR0314714 A BR 0314714A BR 0314714 A BR0314714 A BR 0314714A
Authority
BR
Brazil
Prior art keywords
compounds
treatment
alzheimer
disease
useful
Prior art date
Application number
BR0314714-2A
Other languages
English (en)
Inventor
Roy Hom
Varghese John
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of BR0314714A publication Critical patent/BR0314714A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans

Abstract

"COMPOSTOS PARA O TRATAMENTO DA DOENçA DE ALZHEIMER". A invenção refere-se a compostos de fórmula (I). Esses compostos incluem inibidores da enzima beta-secretase sendo úteis no tratamento da doença de Alzheimer e de outras doenças caracterizadas pela deposição do peptídeo A beta num mamífero. Os compostos da invenção são úteis em composições farmacêuticas e métodos de tratamento na redução de formação do peptídeo A beta.
BR0314714-2A 2002-09-27 2003-09-26 Compostos para o tratamento da doença de alzheimer BR0314714A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41428702P 2002-09-27 2002-09-27
PCT/US2003/030388 WO2004029019A2 (en) 2002-09-27 2003-09-26 Compounds for the treatment of alzheimer’s disease

Publications (1)

Publication Number Publication Date
BR0314714A true BR0314714A (pt) 2005-08-02

Family

ID=32043374

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314714-2A BR0314714A (pt) 2002-09-27 2003-09-26 Compostos para o tratamento da doença de alzheimer

Country Status (8)

Country Link
US (1) US7763646B2 (pt)
EP (1) EP1542964A2 (pt)
JP (1) JP2006501282A (pt)
AU (1) AU2003299101A1 (pt)
BR (1) BR0314714A (pt)
CA (1) CA2500109A1 (pt)
MX (1) MXPA05003220A (pt)
WO (1) WO2004029019A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US20050239836A1 (en) 2004-03-09 2005-10-27 Varghese John Substituted hydroxyethylamine aspartyl protease inhibitors
US7385085B2 (en) 2004-07-09 2008-06-10 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
CA2603404A1 (en) * 2005-03-30 2006-10-05 Boehringer Ingelheim International Gmbh Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
JP5025795B2 (ja) * 2008-06-05 2012-09-12 旭化成ファーマ株式会社 スルホンアミド化合物及びその用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE272096C (pt)
DE479354C (de) * 1926-08-14 1929-07-15 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von 1-Amino-3-dialkylamino-2-propanolen
DE2720915C2 (de) * 1977-05-10 1986-04-17 Kali-Chemie Pharma Gmbh, 3000 Hannover N↓1↓-Acyl-2-hydroxy-1,3-diaminopropane und Arzneimittel mit diesen Verbindungen als Wirkstoff
DE2720968C2 (de) * 1977-05-10 1986-05-07 Kali-Chemie Pharma Gmbh, 3000 Hannover N↓1↓-Acyl-2-hydroxy-1,3-diaminopropane und Arzneimittel
PE20020276A1 (es) * 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER

Also Published As

Publication number Publication date
JP2006501282A (ja) 2006-01-12
MXPA05003220A (es) 2005-07-05
WO2004029019A8 (en) 2005-09-15
AU2003299101A1 (en) 2004-04-19
EP1542964A2 (en) 2005-06-22
WO2004029019A3 (en) 2004-05-27
US7763646B2 (en) 2010-07-27
WO2004029019A2 (en) 2004-04-08
US20060128786A1 (en) 2006-06-15
CA2500109A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BR0306724A (pt) carboxamidas amino substituìdas para tratamento de doença de alzheimer
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
BR0314071A (pt) Derivados de pró-droga de 1,3-diamino-2-hidroxipropano
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
BR0316629A (pt) Uréias e carbamatos substituìdos
BR0210391A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
BR0211122A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BR0314611A (pt) Compostos de tiazol para o tratamento de distúrbios neurodegenerativos
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
MXPA04002785A (es) Aminas sustituidas para tratamiento de enfermedad de alzheimer.
ECSP055696A (es) Acetil 2-hidroxi-1, 3-diaminoalcanos
EA200401114A3 (ru) Замещённые гидроксиэтиламины
MXPA04003245A (es) Hidroxipropilaminas.
ECSP055844A (es) Nuevos compuestos triciclicos
ATE512147T1 (de) Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3
BR0213138A (pt) Métodos de tratar ou prevenir mal de alzheimer e uma doença distinguida por depósito de beta-amilóide no cérebro, de tratar um paciente que tenha, ou de prevenir um paciente de contrair uma doença ou condição, de produzir um complexo de beta-secretase e de inibir a produção de placa beta-amilóide em um animal, composição e uso de um composto
MXPA03011466A (es) Macrociclos utiles en tratamiento de enfermedades de alzheimer.
BR0008112A (pt) Agonistas de 5-ht 1f
BR0314180A (pt) Aminoéteres substituìdos para o tratamento da doença de alzheimer
BR0314714A (pt) Compostos para o tratamento da doença de alzheimer
BR0211121A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
ES2284970T3 (es) Compuestos amina 1,2- y 1,3-diol y su utilizacion para el tratamiento de alzheimer.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]